1. Novartis won’t start testing its autofocus contact lens, co-developed with Google, on people with diabetes in 2016 as anticipated. The drugmaker had previously announced plans to develop two types of lenses, including one that would measure blood glucose levels in diabetes patients. It’s unclear when human clinical trials will begin. (Reuters)
2. The American Diabetes Association called for congressional hearings on insulin pricing, a move described as unusual for a patient group. (Politico)
3. Vice launched a global healthcare channel called Tonic that aims to tell stories about science, global health, and politics. It will focus in part on how the healthcare system in the U.S. changes under President-elect Donald Trump. (Adweek)
4. GlaxoSmithKline submitted its experimental three-in-one inhaled lung drug to the FDA, with a goal of the drug reaching the market by 2017 if it is approved. The inhaler, which contains fluticasone, umeclidinium, and vilanterol, would be used by patients with COPD. (Reuters)
5. Advertisers are rethinking the ways they market products to middle American voters after Trump’s win. A discussion at McCann Worldgroup concluded that many consumers do not want to be like so-called coastal elites. Marketing should be less focused on New York and Los Angeles and more on Des Moines and Scranton, one executive said. (WSJ)
